{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:08:36Z","timestamp":1790734116948,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tumor infiltrating lymphocytes (TILs) have been shown to be associated with the prognosis of breast ductal carcinoma in situ (DCIS). In this systematic review and meta-analysis, we investigated the role of TILs and TIL subsets in predicting the recurrence risk of DCIS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>PubMed, Medline, Web of Science, Embase and Cochrane were searched to identify publications investigating the prognostic role of TILs in DCIS. After study screening, data extraction and risk of bias assessment, a meta-analysis was performed to assess the association between TILs (total TILs, CD4+, CD8+, FOXP3+, PD-L1+ TILs) and the risk of DCIS recurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A pooled analysis indicated that dense stromal TILs in DCIS were associated with a higher recurrence risk (HR 2.11 (95% CI 1.35\u20133.28)). Subgroup analysis showed that touching TILs (HR 4.73 (95% CI 2.28\u20139.80)) was more precise than the TIL ratio (HR 1.49 (95% CI 1.11\u20131.99)) in estimating DCIS recurrence risk. Moreover, the prognostic value of TILs seemed more suitable for patients who are diagnosed with DCIS and then undergo surgery (HR 2.77, (95% CI 1.26\u20136.07)) or surgery accompanied by radiotherapy (HR 2.26, (95% CI 1.29\u20133.95)), than for patients who receive comprehensive adjuvant therapies (HR 1.16, (95% CI 1.35\u20133.28)). Among subsets of TILs, dense stromal PD-L1+ TILs were valuable in predicting higher recurrence risk of DCIS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This systematic review and meta-analysis suggested a non-favorable prognosis of TILs and stromal PD-L1+ TILs in DCIS and indicated an appropriate assessment method for TILs and an eligible population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09883-9","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T01:02:39Z","timestamp":1658106159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Shuang-Ling","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"issue":"41","key":"9883_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/jncimonographs\/lgq027","volume":"2010","author":"K Kerlikowske","year":"2010","unstructured":"Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010(41):139\u201341.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"6","key":"9883_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3322\/caac.21321","volume":"65","author":"EM Ward","year":"2015","unstructured":"Ward EM, DeSantis CE, Lin CC, Kramer JL, Jemal A, Kohler B, et al. Cancer statistics: Breast cancer in situ. CA Cancer J Clin. 2015;65(6):481\u201395.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"9883_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/jnci\/djt067","volume":"105","author":"LJ Solin","year":"2013","unstructured":"Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701\u201310.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"9883_CR4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","volume":"1","author":"SA Narod","year":"2015","unstructured":"Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncol. 2015;1(7):888\u201396.","journal-title":"JAMA Oncol"},{"issue":"10","key":"9883_CR5","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","volume":"7","author":"CR Gil Del Alcazar","year":"2017","unstructured":"Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, et al. Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov. 2017;7(10):1098\u2013115.","journal-title":"Cancer Discov"},{"issue":"1","key":"9883_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"issue":"17","key":"9883_CR7","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1158\/1078-0432.CCR-17-0743","volume":"23","author":"S Hendry","year":"2017","unstructured":"Hendry S, Pang JMB, Byrne DJ, Lakhani SR, Cummings MC, Campbell IG, et al. Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features. Clin Cancer Res. 2017;23(17):5210\u20137.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"9883_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/annonc\/mdw623","volume":"28","author":"G Pruneri","year":"2017","unstructured":"Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, et al. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol. 2017;28(2):321\u20138.","journal-title":"Ann Oncol"},{"key":"9883_CR9","first-page":"70A","volume":"95","author":"E Thompson","year":"2015","unstructured":"Thompson E, Elwood H, Sharma R, Meeker A, Warzecha H, Argani P, et al. The immune microenvironment of breast ductal carcinoma in situ: A pilot study. Lab Investig. 2015;95:70A.","journal-title":"Lab Investig"},{"issue":"4","key":"9883_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ejso.2018.11.005","volume":"45","author":"M Van Bockstal","year":"2019","unstructured":"Van Bockstal M, Lambein K, Smeets A, Slembrouck L, Neven P, Nevelsteen I, et al. Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast. Ejso. 2019;45(4):550\u20139.","journal-title":"Ejso"},{"issue":"10","key":"9883_CR11","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1245\/s10434-019-07562-x","volume":"26","author":"F Darvishian","year":"2019","unstructured":"Darvishian F, Ozerdem U, Adams S, Chun J, Pirraglia E, Kaplowitz E, et al. Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS). Ann Surg Oncol. 2019;26(10):3337\u201343.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"9883_CR12","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/s41416-020-0797-7","volume":"122","author":"MS Toss","year":"2020","unstructured":"Toss MS, Abidi A, Lesche D, Joseph C, Mahale S, Saunders H, et al. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. Br J Cancer. 2020;122(10):1496\u2013506.","journal-title":"Br J Cancer"},{"issue":"1","key":"9883_CR13","doi-asserted-by":"publisher","first-page":"1875637","DOI":"10.1080\/2162402X.2021.1875637","volume":"10","author":"F-F Xu","year":"2021","unstructured":"Xu F-F, Zheng S-F, Xu C, Cai G, Wang S-B, Qi W-X, et al. Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ. Oncoimmunology. 2021;10(1):1875637.","journal-title":"Oncoimmunology"},{"issue":"8","key":"9883_CR14","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41379-018-0040-8","volume":"31","author":"MS Toss","year":"2018","unstructured":"Toss MS, Miligy I, Al-Kawaz A, Alsleem M, Khout H, Rida PC, et al. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Modern Pathol. 2018;31(8):1226\u201336.","journal-title":"Modern Pathol"},{"key":"9883_CR15","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3389\/fonc.2020.01486","volume":"10","author":"A Farolfi","year":"2020","unstructured":"Farolfi A, Petracci E, Serra L, Ravaioli A, Bravaccini S, Ravaioli S, et al. Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ. Front Oncol. 2020;10:1486.","journal-title":"Front Oncol"},{"issue":"1","key":"9883_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-019-05272-2","volume":"177","author":"X-Y Chen","year":"2019","unstructured":"Chen X-Y, Yeong J, Thike AA, Bay BH, Tan PH. Prognostic role of immune infiltrates in breast ductal carcinoma in situ. Breast Cancer Res Treat. 2019;177(1):17\u201327.","journal-title":"Breast Cancer Res Treat"},{"key":"9883_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.breast.2016.07.015","volume":"29","author":"S Luen","year":"2016","unstructured":"Luen S, Virassamy B, Savas P, Salgado R, Loi S. The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016;29:241\u201350.","journal-title":"Breast"},{"issue":"1","key":"9883_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13058-020-01267-w","volume":"22","author":"M Kim","year":"2020","unstructured":"Kim M, Chung YR, Kim HJ, Woo JW, Ahn S, Park SY. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res. 2020;22(1):32.","journal-title":"Breast Cancer Res"},{"key":"9883_CR19","doi-asserted-by":"publisher","first-page":"117437","DOI":"10.1016\/j.lfs.2020.117437","volume":"247","author":"S Bastaki","year":"2020","unstructured":"Bastaki S, Irandoust M, Ahmadi A, Hojjat-Farsangi M, Ambrose P, Hallaj S, et al. PD-L1\/PD-1 axis as a potent therapeutic target in breast cancer. Life Sci. 2020;247:117437.","journal-title":"Life Sci"},{"issue":"23","key":"9883_CR20","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","volume":"24","author":"T Bremer","year":"2018","unstructured":"Bremer T, Whitworth PW, Patel R, Savala J, Barry T, Lyle S, et al. A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk. Clin Cancer Res. 2018;24(23):5895\u2013901.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"9883_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41523-021-00362-1","volume":"8","author":"S Loi","year":"2022","unstructured":"Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, et al. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. NPJ Breast Cancer. 2022;8(1):3.","journal-title":"NPJ Breast Cancer"},{"issue":"32","key":"9883_CR22","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1200\/JCO.2009.21.8560","volume":"27","author":"LL Hughes","year":"2009","unstructured":"Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27(32):5319\u201324.","journal-title":"J Clin Oncol"},{"issue":"33","key":"9883_CR23","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1200\/JCO.2015.60.8588","volume":"33","author":"LJ Solin","year":"2015","unstructured":"Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, et al. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J Clin Oncol. 2015;33(33):3938\u201344.","journal-title":"J Clin Oncol"},{"issue":"10","key":"9883_CR24","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","volume":"32","author":"S Loi","year":"2021","unstructured":"Loi S, Michiels S, Adams S, Loibl S, Budczies J, Denkert C, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021;32(10):1236\u201344.","journal-title":"Ann Oncol"},{"issue":"4","key":"9883_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40291-021-00525-7","volume":"25","author":"B Pellegrino","year":"2021","unstructured":"Pellegrino B, Hlavata Z, Migali C, De Silva P, Aiello M, Willard-Gallo K, et al. Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Mol Diagn Ther. 2021;25(4):409\u201324.","journal-title":"Mol Diagn Ther"},{"key":"9883_CR26","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3389\/fonc.2020.01022","volume":"10","author":"G Kim","year":"2020","unstructured":"Kim G, Pastoriza JM, Condeelis JS, Sparano JA, Filippou PS, Karagiannis GS, et al. The Contribution of Race to Breast Tumor Microenvironment Composition and Disease Progression. Front Oncol. 2020;10:1022.","journal-title":"Front Oncol"},{"issue":"1","key":"9883_CR27","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1634\/theoncologist.2019-0123","volume":"25","author":"CH Chen","year":"2020","unstructured":"Chen CH, Lu YS, Cheng AL, Huang CS, Kuo WH, Wang MY, et al. Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations. Oncologist. 2020;25(1):e16\u201323.","journal-title":"Oncologist"},{"issue":"6","key":"9883_CR28","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/his.14055","volume":"76","author":"AA Thike","year":"2020","unstructured":"Thike AA, Chen X, Koh VCY, Binte Md Nasir ND, JPS Y, Bay BH, et al. Higher densities of tumour-infiltrating lymphocytes and CD4+ T cells predict recurrence and progression of ductal carcinoma in situ of the breast. Histopathology. 2020;76(6):852\u201364.","journal-title":"Histopathology"},{"issue":"2","key":"9883_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/his.13217","volume":"71","author":"I Miligy","year":"2017","unstructured":"Miligy I, Mohan P, Gaber A, Aleskandarany MA, Nolan CC, Diez-Rodriguez M, et al. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. Histopathology. 2017;71(2):258\u201368.","journal-title":"Histopathology"},{"issue":"6","key":"9883_CR30","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00428-019-02735-1","volume":"476","author":"XY Chen","year":"2020","unstructured":"Chen XY, Thike AA, Nasir NDM, Koh VCY, Bay BH, Tan PH. Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence. Virchows Arch. 2020;476(6):825\u201333.","journal-title":"Virchows Arch"},{"key":"9883_CR31","first-page":"108","volume":"98","author":"AA Thike","year":"2018","unstructured":"Thike AA, Koh V, Md Nasir ND, Tan PH. CD68 and CD163 predict recurrence and progression of breast ductal carcinoma in situ. Lab Investig. 2018;98:108.","journal-title":"Lab Investig"},{"issue":"1","key":"9883_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-016-4036-0","volume":"161","author":"MJ Campbell","year":"2017","unstructured":"Campbell MJ, Baehner F, O\u2019Meara T, Ojukwu E, Han B, Mukhtar R, et al. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2017;161(1):17\u201328.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"9883_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-019-05371-0","volume":"178","author":"W Huang","year":"2019","unstructured":"Huang W, Ran R, Shao B, Li H. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019;178(1):17\u201333.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"9883_CR34","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/jmri.27910","volume":"55","author":"T Bian","year":"2022","unstructured":"Bian T, Wu Z, Lin Q, Mao Y, Wang H, Chen J, et al. Evaluating Tumor-Infiltrating Lymphocytes in Breast Cancer Using Preoperative MRI-Based Radiomics. J Magn Reson Imaging. 2022;55(3):772\u201384.","journal-title":"J Magn Reson Imaging"},{"key":"9883_CR35","doi-asserted-by":"publisher","unstructured":"Yamashita N, Hisamatsu Y, Shigechi T, Tokunaga E, Saeki H, Oki E, et al. The immune microenvironment of ductal carcinoma in situ of the breast. Cancer Res. 2019;79(4). https:\/\/doi.org\/10.1158\/15387445.SABCS18-P5-07-07.","DOI":"10.1158\/15387445.SABCS18-P5-07-07"},{"issue":"14","key":"9883_CR36","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/1538-7445.AM2016-1465","volume":"76","author":"M Beguinot-Cornillon","year":"2016","unstructured":"Beguinot-Cornillon M, Dauplat MM, Kwiatkowski F, Lebouedec G, Tixier L, Pomel C, et al. Analysis of tumor-infiltrating lymphocytes (TILs) reveals biologically different subgroups of breast ductal carcinoma in situ. Cancer Res. 2016;76(14):1465.","journal-title":"Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09883-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09883-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09883-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T01:02:45Z","timestamp":1658106165000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09883-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9883"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09883-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"782"}}